EXAS - EXACT SCIENCES CORP
IEX Last Trade
57.6
-0.120 -0.208%
Share volume: 30,169
Last Updated: Fri 27 Dec 2024 08:30:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$57.72
-0.12
-0.21%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-21 | 2023-05-09 | 2023-08-01 | 2023-11-01 | 2024-02-21 | 2024-05-08 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 6.307 B | 6.227 B | 6.304 B | 6.356 B | 6.421 B | 6.471 B | 6.376 B | 6.673 B | |
| Current Assets | 1.049 B | 982.257 M | 1.091 B | 1.174 B | 1.148 B | 1.194 B | 1.120 B | 1.452 B | |
| Inventories | 114.699 M | 118.259 M | 124.092 M | 130.770 M | 132.841 M | 127.475 M | 128.534 M | 127.373 M | |
| Other Current Assets | 75.487 M | 73.898 M | 85.274 M | 89.129 M | 81.536 M | 85.627 M | 99.059 M | 114.467 M | |
| Short Term Investments | 75.487 M | 73.898 M | 85.274 M | 89.129 M | 81.536 M | 85.627 M | 99.059 M | 114.467 M | |
| Total Receivables | 189.206 M | 158.043 M | 183.371 M | 178.317 M | 199.403 M | 203.623 M | 240.584 M | 263.865 M | |
| Current Cash | 669.114 M | 632.057 M | 698.647 M | 775.712 M | 734.406 M | 777.644 M | 652.093 M | 946.782 M | |
| Total Non-current Assets | 5.258 B | 5.245 B | 5.213 B | 5.182 B | 5.273 B | 5.277 B | 5.256 B | 5.221 B | |
| Property Plant Equipment | 670.506 M | 684.756 M | 684.574 M | 686.602 M | 692.404 M | 698.354 M | 702.041 M | 703.083 M | |
| Other Assets | 88.739 M | 90.577 M | 91.872 M | 89.536 M | 150.748 M | 177.387 M | 178.085 M | 167.468 M | |
| Intangible Assets | 1.978 B | 1.956 B | 1.933 B | 1.911 B | 1.913 B | 1.890 B | 1.867 B | 1.843 B | |
| Goodwill | 2.345 B | 2.346 B | 2.346 B | 2.346 B | 2.367 B | 2.367 B | 2.367 B | 2.367 B | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 6.307 B | 6.227 B | 6.304 B | 6.356 B | 6.421 B | 6.471 B | 6.376 B | 6.673 B | |
| Total liabilities | 3.198 B | 3.184 B | 3.247 B | 3.299 B | 3.300 B | 3.326 B | 3.244 B | 3.481 B | |
| Total current liabilities | 423.676 M | 412.747 M | 367.354 M | 488.057 M | 476.513 M | 514.701 M | 685.109 M | 668.642 M | |
| Accounts Payable | 63.583 M | 74.916 M | 86.713 M | 75.080 M | 73.558 M | 78.816 M | 60.498 M | 52.980 M | |
| Other liabilities | 354.998 M | 352.459 M | 344.380 M | 330.816 M | 341.771 M | 335.982 M | 329.384 M | 326.678 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 50.000 M | 50.000 M | 50.000 M | 298.810 M | 248.923 M | |
| Long term debt | 2.235 B | 2.236 B | 2.360 B | 2.312 B | 2.313 B | 2.314 B | 2.067 B | 2.318 B | |
| Other liabilities | 354.998 M | 352.459 M | 344.380 M | 330.816 M | 341.771 M | 335.982 M | 329.384 M | 326.678 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 3.109 B | 3.043 B | 3.058 B | 3.057 B | 3.121 B | 3.145 B | 3.133 B | 3.192 B | |
| Common stock | 176.997 M | 177.626 M | 178.574 M | 180.204 M | 180.649 M | 181.149 M | 182.350 M | 184.313 M | |
| Retained earnings | -3.137 B | -3.265 B | -3.339 B | -3.420 B | -3.419 B | -3.469 B | -3.579 B | -3.595 B |